Industries > Pharma > Pharma Wholesale and Distribution Market Forecasts 2017-2027
Pharma Wholesale and Distribution Market Forecasts 2017-2027
Branded and Generic Drug Distribution, Leading National Markets, Leading Wholesalers, US, Europe, Japan and China
The pharma wholesale and distribution market is estimated at $893.69 million in 2016 and is expected to grow at a CAGR of 6.0% in the first half of the forecast period. The market is expected to grow at a CAGR of 5.2% from 2017-2027. In 2016, the branded drugs submarket held 79.5% share of the pharma wholesale and distribution market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 265-page report you will receive 83 tables and 97 figures – all unavailable elsewhere.
The 265-page report provides clear detailed insight into the pharma wholesale and distribution market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Pharma Wholesale and Distribution market forecasts from 2017-2027
• This report also breaks down the revenue forecast for main submarkets:
– Branded Drugs
– Generic Drugs
– Other Medicines
• This report provides individual revenue forecasts to 2027 for these national markets:
– The US
– Japan
– Germany
– France
– Italy
– Spain
– The UK
– China
– Brazil
– Russia
– India
• Our study includes SWOT and STEP analysis of this industry and market.
• Our study discusses the selected leading companies that are the major players in the pharma wholesale and distribution industry:
– McKesson
– Cardinal Health
– AmerisourceBergen
– Walgreens Boots Alliance
– MEDIPAL HOLDINGS
– The PHOENIX Group
– SINOPHARM
– Alfresa Holdings
– SUZUKEN
– Shanghai Pharmaceutical Holdings
• Our report explains issues, events and shifts affecting that industry and market from 2016, including these influences:
– Roles of pharmaceutical wholesalers – activities, changes and prospects
– Revenues, costs and profits
– Direct-to-pharmacy (DTP) activities
– Full-line wholesalers (FLWs), short-line wholesalers (SLWs) and the drug distribution chain, including logistical service providers
– Technologies and services – progress in supplying pharmacies, clinics and hospitals, serving healthcare professionals, governments, payers and patients
– Forward buying, fee-for-service systems and the rise of retail pharmacies.
• Our investigation also discusses other aspects of that industry, including these forces:
– Parallel trade – activities, policies, challenges and effects
– Inventory management agreements, clawback, reimbursement and discounts
– Rise of specialty medicines, including biologics, vaccines and biosimilars – opportunities for intermediaries, including cold chain distribution networks
– Actions against drug counterfeiting – security of pharmaceutical supply chains
– Changes to regulations and healthcare budgets – policies affecting trade
Visiongain’s study is intended for anyone requiring commercial analyses for the pharma wholesale and distribution market. You find data, trends and predictions.
Buy our report today Pharma Wholesale and Distribution Market Forecasts 2017-2027: Branded and Generic Drug Distribution, Leading National Markets, Leading Wholesalers, US, Europe, Japan and China.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Global Pharma Wholesale and Distribution Industry and Market Overview
1.2 Benefits of This Report
1.3 How This Report Delivers
1.4 Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Introduction to Pharma Wholesale and Distribution
2.1 The Role of Pharmaceutical Wholesalers: The Middlemen of the Pharmaceutical Industry
2.1.1 Full-Line Wholesalers (FLWs)
2.1.2 Short-Line Wholesalers (SLWs)
2.2 The Chain of Distribution: Wholesalers vs. Logistic Service Providers
2.2.1 Secondary Wholesalers
2.2.2 Direct-to-Pharmacy (DTP) Distribution is Becoming More Prevalent
2.2.3 Major Wholesalers: Distribution of a Large Number of Products to Generate High Profits
2.2.4 Distribution from Large to Small Wholesalers: A Lengthy Distribution Chain
2.2.5 Pharmacy Benefit Managers
2.3 Generative Revenue and Profit
2.3.1 Forward Buying to Avoid Price Increases
2.3.2 Fee-for-Service: A Clear Pricing Structure
2.3.3 Discounts: Incentives for Prompt Payment or Bulk Purchases
2.3.4 Reimbursement and Wholesalers
2.3.5 Clawback: The Recovery of Reimbursement Costs by Governments
2.3.6 Parallel Trade: Different Attitudes in Europe and the US
3. The World Pharmaceutical Wholesale and Distribution Market: 2016-2027
3.1 The World Pharmaceutical Wholesale and Distribution Market in 2015, Restricted by Government Price Reductions and Generic Substitution
3.2 The Pharmaceutical Wholesale and Distribution Industry: World Market Forecast, 2016-2027
3.3 Branded and Generic Drugs: Revenue vs. Profit, 2016-2027
3.3.1 Branded and Generic Drugs: Revenue Generation, 2016
3.3.2 Branded Drugs: Revenue Forecast, 2016-2027
3.3.3 Generic Drugs: Revenue Forecast, 2016-2027
4. Pharmaceutical Wholesale and Distribution Industry: Leading National Markets, 2016-2027
4.1 The Leading National Markets: the US Dominates in 2016
4.2 The Future of the Leading National Markets: Will the US Continue to Dominate the Market?
4.3 The US Pharma Wholesale and Distribution Market
4.3.1 The Budget Control Act and its Effect on the US Wholesale and Distribution Industry
4.3.2 Legislation to Prevent Counterfeit Drugs Can Differ Between States
4.3.3 An Increase in Fee-For-Service Activity
4.3.4 Pharma Wholesale and Distribution Market in the US: Market Forecast, 2016-2027
4.4 The Leading European (EU5) Pharma Wholesale and Distribution Markets
4.4.1 The Difference Between the US and European Markets
4.4.2 State-Funded Healthcare and Reimbursement
4.4.3 EU5: Market Forecast, 2016-2027
4.4.4 Germany: Pharma Wholesale and Distribution Market, 2016
4.4.5 France: Pharma Wholesale and Distribution Market, 2015
4.4.6 Italy: Pharma Wholesale and Distribution Market, 2016
4.4.7 Spain: Pharma Wholesale and Distribution Market, 2016
4.4.8 UK: Pharma Wholesale and Distribution Market, 2016
4.5 Japan: Pharma Wholesale and Distribution Market, 2016
4.5.1 Drug Pricing and Performing Fees in Japan
4.5.2 Japan: Pharma Wholesale and Distribution Market Forecast, 2016-2027
4.6 China: Pharma Wholesale and Distribution Market, 2016
4.6.1 China: Leading Pharma Wholesale and Distribution Companies, 2016
4.6.2 China: Pharma Wholesale and Distribution Market Forecast, 2016-2027
4.7 Brazil: Pharma and Wholesale Distribution Market, 2016
4.7.1 Drug Price Controls in Brazil
4.7.2 Brazil: Leading Pharma Wholesale and Distribution Companies, 2016
4.7.3 Brazil: Pharma Wholesale and Distribution Market Forecast, 2016-2027
4.8 India: Pharma Wholesale and Distribution Market, 2016
4.8.1 India: Pharma Wholesale and Distribution Market Forecast, 2016-2027
4.9 Russia: Pharma Wholesale and Distribution Market, 2016
4.9.1 Drug Pricing Controls in Russia
4.9.2 Market Trends in Russia
4.9.3 Russia: Pharma Wholesale and Distribution Market Forecast, 2016-2027
4.10 Conclusion
5. Leading Pharma Wholesalers and Distributors In 2016: Current and Future Performance
5.1 The Leading Pharma Wholesalers and Distribution Companies in 2016
5.2 Revenue vs. Profit
5.3 Leading Pharma Wholesale and Distribution Companies: Grouped Forecasts, 2016-2027
5.4 McKesson: The Oldest and Largest Healthcare Services Company in the US
5.4.1 McKesson: Historical Performance, 2010-2015
5.4.2 Future Strategies: Consummate Acquisitions to Complement Existing Business or Expand Businesses
5.4.3 McKesson: Revenue Forecast, 2016-2027
5.5 Cardinal Health: The World’s Third Largest Pharma Wholesaler
5.5.1 Cardinal Health: Historical Performance, 2010-2015
5.5.2 Will CVS Joint Venture and Acquisitions Stimulate Future Growth?
5.5.3 Cardinal Health: Revenue Forecast, 2016-2027
5.6 AmerisourceBergen: Third Largest Global Pharma Wholesaler and Distributor
5.6.1 AmerisourceBergen: Historical Performance, 2016
5.6.2 Will Contracts with Walgreens and Alliance Boots Drive Future Growth?
5.6.3 AmerisourceBergen: Revenue Forecast, 2016-2027
5.7 Walgreens Boots Alliance: The Largest Drugstore Chain in the US and Global Wholesale and Distribution Network
5.7.1 Walgreens Boots Alliance: Historical Performance, 2011-2016
5.7.2 Acquisitions and Future Strategies of Walgreens Boots Alliance
5.7.3 Walgreens Boots Alliance: Revenue Forecast, 2016-2027
5.8 MEDIPAL HOLDINGS CORPORATION: Japan’s Leading Pharmaceutical Wholesaler
5.8.1 MEDIPAL HOLDINGS CORPORATION: Historical Performance, 2011-2015
5.8.2 Future Strategies of MEDIPAL HOLDINGS CORPORATION: Revised Business Portfolio with Diverse Sources of Earnings
5.8.3 MEDIPAL HOLDINGS CORPORATION: Revenue Forecast, 2016-2027
5.9 Phoenix Group: Biggest European Wholesalers
5.9.1 The PHOENIX Group: Historical Performance, 2011-2015
5.9.2 Future Strategies of the PHOENIX Group: Selective Acquisition
5.9.3 The PHOENIX Group: Revenue Forecast, 2016-2027
5.10 SINOPHARM: The Leading Pharmaceutical Wholesaler and Distributor in China
5.10.1 SINOPHARM: Historical Performance, 2011-2016
5.10.2 Future Strategies of SINOPHARM: Provide Comprehensive Services and Wider Business Coverage
5.10.3 SINOPHARM: Revenue Forecast, 2016-2027
5.11 Alfresa Holdings: Second Largest Pharmaceutical Wholesaler and Distributor in Japan
5.11.1 Alfresa Holdings: Historical Performance, 2011-2016
5.11.2 Future Strategy of Alfresa Holdings: To Focus on Expanding Business Fields and Increasing Footprint
5.11.3 Alfresa Holdings: Revenue Forecast, 2016-2027
5.12 SUZUKEN CO., LTD: The First Nationwide Wholesaler of Japan
5.12.1 SUZUKEN CO. LTD: Historical Performance, 2011-2015
5.12.2 Future Strategies of SUZUKEN CO., LTD: Five Growth Initiatives and Special Focus on Diabetes Field
5.12.3 SUZUKEN CO., LTD: Revenue Forecast, 2016-2027
5.13 Shanghai Pharmaceuticals Holding: China’s Second Largest Wholesaler
5.13.1 Shanghai Pharmaceuticals Holding: Historical Performance, 2011-2015
5.13.2 Future Strategies of Shanghai Pharma: Expansion of Three Leading Regions in China
5.13.3 Shanghai Pharma: Revenue Forecast, 2016-2027
6. Qualitative Analysis of the Pharma Wholesale and Distribution Market
6.1 The Strengths and Weaknesses of the Pharma Wholesale and Distribution Market, 2016
6.1.1 The Insatiable Demand for Drugs: A Recession Proof Industry?
6.1.2 Wholesalers Do More than Deliver Drugs
6.1.3 Large Companies Dominate the Market
6.1.4 Despite High Revenues, Profit Margins Are Low
6.1.5 Government-Induced Drug Price Pressures Restrict Profits
6.1.6 The Problem of Counterfeit Drugs
6.2 The Opportunities and Threats of the Pharma Wholesale and Distribution Market, 2016-2027
6.2.1 The Demand for Pharmaceuticals is Increasing
6.2.2 The Increasing Use of speciality Drugs Will Drive Growth
6.2.3 The Increasing Use of Generic Drugs Will Limit Revenue, But Drive Profit Generation
6.2.4 The Promotion of Drug Therapy in the US
6.2.5 Globalisation: The Major National Markets are Dominated by Few Companies
6.2.6 Increased Adoption of the DTP Distribution Model
6.2.7 The Threat of Healthcare Budget Cuts
6.2.8 Do Large Pharmacy Chains Pose a Threat?
6.2.9 Does the Diversion and Re-Importation of Medicines Pose a Threat to the Industry?
6.2.10 The Threat of Industry Consolidation
6.3 Social, Technological, Economical and Political Factors Influencing the Market, 2016-2027 (STEP Analysis)
6.3.1 Political Factor: The Impact of Recent Regulatory Changes in the EU
6.3.2 Political Factor: Combating Counterfeit Medicines
7. Conclusions
7.1 The Future of the Pharma Wholesale and Distribution Market
7.2 The Leading National Pharma Wholesale and Distribution Markets
7.3 The Leading Companies in the Pharma Wholesale and Distribution Industry
7.4 Trends in the Pharma Wholesale and Distribution Industry
7.4.1 Generics Will Threaten Revenue
7.4.2 Manufacturers Will Deliver More Drugs Directly
7.4.3 There Will Be Greater Demand for Speciality Medicines
7.4.4 Consolidation Will Drive Growth
7.4.5 Anti-Counterfeiting Demands Will Add to Wholesalers’ Costs
Associated Visiongain Reports
Visiongain REPORT SALES ORDER FORM
APPENDIX A
About Visiongain
APPENDIX B
Visiongain report evaluation form
List of Tables
Table 1.1 Foreign Currency Exchange Rates to $US, 2016
Table 2.1 Use of DTP Model in the UK, 2007-2012
Table 3.1 Pharmaceutical Wholesale and Distribution: World Market Forecast ($bn), AGR (%), CAGR (%), 2016-2027
Table 3.2 Pharmaceutical Wholesale and Distribution: Branded Drugs, Generic Drugs and Others, Revenue ($bn) Forecasts, AGR (%), CAGR (%) and Market Shares (%), 2016-2027
Table 3.3 Wholesale and Distribution of Branded Drugs: Revenue ($bn) and Market Share (%) Forecast, 2016-2027
Table 3.4 Wholesale and Distribution of Generic Drugs: Revenue ($bn) and Market Share (%) Forecast, 2016-2027
Table 4.1 Pharma Wholesale & Distribution Leading National Markets: Revenues ($bn) and Market Share (%), 2016
Table 4.2 Pharma Wholesale & Distribution Leading National Markets: Revenue ($bn) Forecasts, AGR (%) and CAGR (%), 2016-2027
Table 4.4 US Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
Table 4.5 Price Controls in Europe, 2016
Table 4.6 EU5 Pharma Wholesale & Distribution Market: Revenue ($bn) Forecasts, AGR (%) and CAGR (%), 2016-2027
Table 4.7 German Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
Table 4.8 French Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
Table 4.9 Italian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
Table 4.10 Spanish Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
Table 4.11 UK Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
Table 4.12 Percentage of the Population Ages 60+ in the US, Europe, Japan, China and India, 2015 and 2030
Table 4.13 Japanese Pharmaceutical Wholesale and Distribution Market: Drug Price Revision Growth (%), 2007-2016
Table 4.14 Japanese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
Table 4.15 Chinese Pharma Wholesale & Distribution: Revenue ($bn) and Market Shares (%) of Leading Companies, 2016
Table 4.16 Chinese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
Table 4.17 Brazilian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
Table 4.18 Indian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
Table 4.19 Russian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
Table 5.1 Leading Companies in the Pharmaceutical Wholesale and Distribution Market: Revenues ($bn) and Market Shares (%), 2016
Table 5.2 Leading Pharmaceutical Wholesale and Distribution Companies: Revenue Forecasts ($bn), AGR (%) and CAGR (%), 2016-2027
Table 5.3 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%) for 2016, 2021 and 2027
Table 5.4 McKesson, Distribution Solutions: Services and Customers, 2016
Table 5.5 McKesson, Technology Solutions: Services and Customers, 2016
Table 5.6 McKesson: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2010-2015
Table 5.7 McKesson: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.8 McKesson: Gross Profit ($bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.9 Acquisitions by McKesson, 2007-2017
Table 5.10 McKesson: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.11 Cardinal Health: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Operating Earnings ($bn), AGR (%) and CAGR (%), 2010-2015
Table 5.12 Cardinal Health: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.13 Cardinal Health: Operating Earnings ($bn) and Annual Growth (%) Breakdown by Business Segment, 2014-2015
Table 5.14 Cardinal Health: Revenue ($bn) and Revenue Share (%) Breakdown by Customer, 2015
Table 5.15 Selected Acquisitions by Cardinal Health and their Line of Business, 2007-2017
Table 5.16 Cardinal Health: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.17 AmerisourceBergen: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
Table 5.18 AmerisourceBergen: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
Table 5.19 AmerisourceBergen: Gross Profit ($bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
Table 5.20 AmerisourceBergen: Revenue ($bn) and Revenue Share (%) Breakdown by Customer, 2016
Table 5.21 Acquisitions by AmerisourceBergen and their Line of Business, 2007-2017
Table 5.22 AmerisourceBergen: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.23 Walgreens Boots Alliance: Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
Table 5.24 Walgreens Boots Alliance: Pharmaceutical Wholesale Revenue ($bn), AGR (%), and CAGR (%) Forecast, 2016-2027
Table 5.25 MEDIPAL Holdings: Consolidated Subsidiary Companies, 2016
Table 5.26 MEDIPAL Holdings: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2015
Table 5.27 MEDIPAL Holdings: Revenue (¥bn, $bn) and Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.28 MEDIPAL Holdings: Operating Income ($bn, ¥bn), Operating Income Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.29 MEDIPAL Holdings: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.30 PHOENIX Group: Subsidiary Companies, 2015
Table 5.31 PHOENIX Group: Historical Revenue (€bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (€bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2015
Table 5.32 PHOENIX Group: Revenue (€bn, $bn), Revenue Share (%) Breakdown by Region, 2014
Table 5.33 PHOENIX Group: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.34 SINOPHARM Group: Historical Revenue (RMBbn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (RMBbn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
Table 5.35 SINOPHARM Group: Revenue (RMBbn, $bn) and Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
Table 5.36 SINOPHARM Group: Operating Profit (RMBbn, $bn), Operating Profit Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
Table 5.37 SINOPHARM Group: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.38 Alfresa Holdings: List of Significant Subsidiaries and Affiliates, 2016
Table 5.39 Alfresa Holdings: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
Table 5.40 Alfresa Holdings: Business Strategies, 2013-2016
Table 5.41 Alfresa Holdings: Revenue (¥bn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
Table 5.42 Alfresa Holdings: Gross Profit (¥bn, $bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
Table 5.43 Alfresa Holdings: Challenges for the 16-18 Mid-term Management Plan - Break Through to Tomorrow, 2016
Table 5.44 Alfresa Holdings: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.45 SUZUKEN: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2015
Table 5.46 SUZUKEN: Revenue (¥bn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.47 SUZUKEN: Operating Income (¥bn, $bn), Operating Income Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.48 SUZUKEN: Revenue (¥bn, $bn), Revenue Share (%) Breakdown for Pharmaceuticals Distribution Segment by Region, 2014
Table 5.49 SUZUKEN: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.50 Shanghai Pharmaceuticals Holding: Historical Revenue (RMBbn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (RMBbn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
Table 5.51 Shanghai Pharmaceuticals Holding: Revenue (RMBbn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
Table 5.52 Shanghai Pharmaceuticals Holding: Operating Profit (RMBbn, $bn), Operating Profit Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
Table 5.53 Shanghai Pharmaceuticals Holding: Distribution Revenue (RMBbn, $bn), Distribution Revenue Share (%) Breakdown by Region, 2016
Table 5.54 Shanghai Pharmaceuticals Holding: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 6.1 The Pharmaceutical W&D Market: Strengths and Weaknesses, 2016
Table 6.2 The Pharmaceutical W&D Market: Opportunities and Threats, 2016-2027
Table 6.3 Strengths and Weaknesses of the DTP Distribution Model, 2016
Table 6.4 ITR Ratings and Corresponding Reimbursement Rates, 2016
Table 6.5 Social, Technological, Economic and Political Factors Influencing the Pharmaceutical Wholesale and Distribution Market (STEP Analysis), 2016-2027
List of Figures
Figure 1.1 Forecast Global Population Over the Age of 65 Years (millions), Annual Growth Rate (%), 2016-2027
Figure 1.2 Routes of Drug Distribution, 2016
Figure 2.1 Routes of Drug Distribution, 2016
Figure 3.1 The Global Pharmaceutical Wholesale and Distribution Market: Drivers and Restraints, 2017
Figure 3.2 Pharmaceutical Wholesale and Distribution: World Market Forecast ($bn), 2016-2027
Figure 3.3 Branded Drugs, Generic Drugs and Others: Market Shares (%), 2016
Figure 3.4 Branded Drugs, Generic Drugs and Others: Market Shares (%), 2021
Figure 3.5 Branded Drugs, Generic Drugs and Others: Market Shares (%), 2027
Figure 3.6 Wholesale and Distribution of Branded Drugs, Generic Drugs and Others: Revenue Forecasts ($bn), 2016-2027
Figure 3.7 Wholesale and Distribution of Branded Drugs: Revenue ($bn) Forecast, 2016-2027
Figure 3.8 Wholesale and Distribution of Generic Drugs: Revenue ($bn) Forecast, 2016-2027
Figure 4.1 Pharma Wholesale & Distribution Leading National Markets: Shares (%), 2016
Figure 4.2 Pharma Wholesale & Distribution Leading National Markets: Shares (%), 2021
Figure 4.3 Pharma Wholesale & Distribution Leading National Markets: Shares (%), 2027
Figure 4.4 Market Share (%) Breakdown of the US Market: The 3 Leading Companies, 2016
Figure 4.5 US Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2016-2027
Figure 4.6 US Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 4.7 EU5 Pharma Wholesale & Distribution Market Shares (%), 2016, 2021 and 2027
Figure 4.8 EU5 Pharma Wholesale & Distribution Market: Revenue ($bn) Forecasts, 2016-2027
Figure 4.9 EU Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 4.10 German Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2016-2027
Figure 4.11 German Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 4.12 French Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2016-2027
Figure 4.13 French Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 4.14 Italian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2016-2027
Figure 4.15 Italian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 4.16 Spanish Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2016-2027
Figure 4.17 Spanish Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 4.18 UK Pharma Wholesale & Distribution Market: Revenue ($bn), 2016-2027
Figure 4.19 UK Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 4.20 Percentage of the Population Ages 65+ in the US, Europe, Japan, China and India, 2015 and 2030
Figure 4.21 Japanese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2016-2027
Figure 4.22 Japanese Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 4.23 Chinese Pharma Wholesale & Distribution: Market Shares (%) of Leading Companies, 2016
Figure 4.24 Chinese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2016-2027
Figure 4.25 Chinese Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 4.26 Brazilian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2016-2027
Figure 4.27 Brazilian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 4.28 Pharma Wholesale & Distribution Model in India, 2016
Figure 4.29 Indian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2016-2027
Figure 4.30 Indian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 4.31 Russian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2016-2027
Figure 4.32 Russian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 5.1 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2016
Figure 5.2 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2021
Figure 5.3 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2027
Figure 5.4 Leading Pharmaceutical W&D Companies: Drivers and Restraints, 2017
Figure 5.5 McKesson: Historical Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) and Gross Profit AGR (%), 2010-2015
Figure 5.6 McKesson: Revenue Share (%) Breakdown by Business Segment, 2015
Figure 5.7 McKesson: Gross Profit Share (%) Breakdown by Business Segment, 2015
Figure 5.8 McKesson: Revenue ($bn) Forecast, 2016-2027
Figure 5.9 McKesson: Drivers and Restraints, 2017
Figure 5.10 Cardinal Health: Historical Revenue ($bn), Revenue AGR (%), Operating Earnings ($bn) and Operating Earnings AGR(%), 2010-2015
Figure 5.11 Cardinal Health: Revenue Share (%) Breakdown by Business Segment, 2015
Figure 5.12 Cardinal Health: Revenue Share (%) Breakdown by Customer, 2015
Figure 5.13 Cardinal Health: Revenue ($bn) Forecast, 2016-2027
Figure 5.14 Cardinal Health: Drivers and Restraints, 2016-2027
Figure 5.15 AmerisourceBergen: Historical Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) and Gross Profit AGR (%), 2011-2016
Figure 5.16 AmerisourceBergen: Revenue Share (%) Breakdown by Business Segment, 2016
Figure 5.17 AmerisourceBergen: Revenue ($bn) Breakdown by Customer, 2015
Figure 5.18 AmerisourceBergen: Revenue ($bn) Forecast, 2016-2027
Figure 5.19 AmerisourceBergen: Drivers and Restraints, 2017
Figure 5.20 Walgreens Boots Alliance: Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) and Gross Profit AGR (%), 2011-2016
Figure 5.21 Walgreens Boots Alliance: Revenue ($bn) Forecast, 2016-2027
Figure 5.22 Alliance Boots: Drivers and Restraints, 2016-2027
Figure 5.23 MEDIPAL Holdings: Historical Revenue (¥bn), Revenue AGR (%), Gross Profit (¥bn) and Gross Profit AGR (%), 2011-2015
Figure 5.24 MEDIPAL Holdings: Revenue Share (%) Breakdown by Business Segment, 2015
Figure 5.25 MEDIPAL Holdings: Operating Income Share (%) Breakdown by Business Segment, 2015
Figure 5.26 MEDIPAL Holdings: Revenue ($bn) Forecast, 2016-2027
Figure 5.27 MEDIPAL Holdings: Drivers and Restraints, 2017
Figure 5.28 PHOENIX Group: Historical Revenue (€bn), Revenue AGR (%), Gross Profit (€bn) and Gross Profit AGR (%), 2011-2015
Figure 5.29 PHOENIX Group: Revenue Share (%) Breakdown by Region, 2014
Figure 5.30 PHOENIX Group: Revenue ($bn) Forecast, 2016-2027
Figure 5.31 PHOENIX Group Drivers and Restraints, 2017
Figure 5.32 SINOPHARM Group: Historical Revenue (RMBbn), Revenue AGR (%), Gross Profit (RMBbn) and Gross Profit AGR (%), 2011-2016
Figure 5.33 SINOPHARM Group: Revenue ($bn) Forecast, 2016-2027
Figure 5.34 SINOPHARM Group: Drivers and Restraints, 2017
Figure 5.35 Alfresa Holdings: Historical Revenue (¥bn), Revenue AGR (%), Gross Profit (¥bn), Gross Profit AGR (%), 2011-2016
Figure 5.36 Alfresa Holdings: Revenue Share (%) Breakdown by Business Segment, 2016
Figure 5.37 Alfresa Holdings: Gross Profit Share (%) Breakdown by Business Segment, 2016
Figure 5.38 Alfresa Holdings: Revenue ($bn) Forecast, 2016-2027
Figure 5.39 Alfresa Holdings: Drivers and Restraints, 2017
Figure 5.40 SUZUKEN: Historical Revenue (¥bn), Revenue AGR (%), Gross Profit (¥bn) and Gross Profit AGR (%), 2011-2015
Figure 5.41 SUZUKEN: Revenue Share (%) Breakdown by Business Segment, 2015
Figure 5.42 SUZUKEN: Operating Income Share (%) Breakdown by Business Segment, 2015
Figure 5.43 SUZUKEN: Revenue Share (%) Breakdown by Region in Japan, 2014
Figure 5.44 SUZUKEN: Revenue ($bn) Forecast, 2016-2027
Figure 5.45 SUZUKEN: Drivers and Restraints, 2017
Figure 5.46 Shanghai Pharmaceuticals Holding: Historical Revenue (RMBbn), Revenue AGR (%), Gross Profit (RMBbn) and Gross Profit AGR (%), 2011-2016
Figure 5.47 Shanghai Pharmaceuticals Holding: Revenue Share (%) Breakdown by Business Segment, 2016
Figure 5.48 Shanghai Pharmaceuticals Holding: Revenue Share (%) Breakdown by Region, 2016
Figure 5.49 Shanghai Pharmaceuticals Holding: Revenue ($bn) Forecast, 2016-2027
Figure 5.50 Shanghai Pharmaceuticals Holding: Drivers and Restraints, 2017
Figure 6.1 Comparison of the Wholesale and DTP Routes of Distribution, 2016
Figure 7.1 Pharmaceutical Wholesale and Distribution: Global Market Forecasts ($bn) by Submarket, 2016-2027
Figure 7.2 Leading National Pharmaceutical Wholesale and Distribution Markets: Revenue Projections ($bn), 2016, 2021 and 2027
Figure 7.3 Leading Pharmaceutical Wholesale and Distribution Companies: Revenue ($bn) Projections 2016, 2021 and 2027
36.6 Group
AAH Pharmaceuticals
AccessClosure
ADG Apotheken-Dienstleistungsgesellschaft mbH
Admenta Italia
Alfresa Corporation
Alfresa Healthcare Corporation
Alfresa Holdings
Alfresa Medical Service Corporation
Alfresa Nikken Sangyo Corporation
Alfresa Pharma Corporation
Alfresa System Corporation
Alliance Boots
Alliance Healthcare
Alphega Network
AmerisourceBergen
Apokjeden AS
Apollo Medical Holdings
ARATA CORPORATION
AssuraMed
ASTIS Co.
AstraZeneca
Athos Farma
Barr Pharmaceuticals
Bayer
Biologics Inc
Bristol-Myers Squibb
Brocacef Groep NV
Cardinal Foods
Cardinal Health
Cardinal Health China
CareFusion
Catalent Pharma Solutions
Celesio AG
Celesio UK
CERP BretagneNord
CERP Network
CERP Rouen
China Health Systems
Chuo Unyu Co.
Cofares
Comifar
Comifar Group
Cordis
CoverMyMeds LLC
CS YAKUHIN CO.
CVS Caremark
Daiichi Sankyo Propharma Co
DEA
Dong Ying (Jiangsu) Pharmaceuticals Co.
DrogariasTamoio Network
Drug Trading Company
Emart Company
ERP Rhin Rhone Mediterranee
Express Scripts
Gilead Sciences
GlaxoSmithKline (GSK)
Guangzhou Pharmaceutical Company
Guangzhou Pharmaceuticals Corporation (GP Corp)
Hanshin Dispensing Pharmacy Holdings Co.
Harvard Drug
Healthcare Solutions Holding
Hefame
Johnson & Johnson
Katz Group
Kenzmedico Co.
Kinray
Kowa Pharmaceuticals Co.
Libra AG
Life Medicom Co.
LloydsPharmacy
McKesson
McQueary Brothers of Springfield
Medicine Shoppe Canada
Medipal Holdings
Mediq Apotheken Nederland B.V.
Meisho Co.
Metro Medical Supply
MSD
Nakano Yakuhin Co.
NaviHealth
Nihon Apoch Co
Nomeco
Novation LLC
Novodata Zrt
Odashima Limited
Oncology Therapeutics
Oncoprod
Outcomes Incorporated
P.JD. Network
Panpharma
Pfercos Co.
Pfizer
PharMEDium Healthcare Holdings
PHOENIX Arzneiwarengroßhandlung Ges.m.b.H.
PHOENIX Farmacija d.d.
PHOENIX Group
PHOENIX Lékárenský velkoobchod, a.s.
PHOENIX Pharma d.o.o.
PHOENIX Pharma DOOEL
PHOENIX Pharma Polska Sp. z o.o.
PHOENIX Pharma S.A.S
PHOENIX Pharma Zrt.
PHOENIX Pharmahandel
PHOENIX Zdravotnícke zásobovanie
Polish Pharmaceutical Council (NRA)
Polska Grupa Farmaceutyczna, Torfarm
Premium Purchasing Partners LP
Profarma
Prosper
Protek
PSS World Medical
QINGDAO NESCO MEDICAL CO.
Raintree Oncology Services
Ratiopharm
Red Oak
Rexall Health
RYUYAKU CO.
S.D.Next Co.
Sanacorp
Sandoz
Sanki Clinical Link Co.
Sanki Corporation
Sanki MediHeart Limited
Sanki Wellbe Co., Ltd. S-Care Mate Co.
Sanofi
Sanwa Kagaku Kenkyusho Co.
Sciclone Trade
SEIWA SANGYO CO.
Shanghai Pharmaceuticals
Shikoku Alfresa Corporation
Shinsegai Group
Shoyaku Co.
SIA International
SIA Tamro
SINOPHARM Group Co.
Sonexus Health
St. Francis Group
SUNPHARMA
SUZUKEN
Suzuken Iwate Co.
Suzuken Okinawa Yakuhin Co.
TAMPEI NAKATA CO.
Tamro AB
Tamro Eesti OÜ
Tamro Oyj
Tokiwa Yakuhin Co
Tradex International
UAB Tamro
US Oncology Holdings
Vantage Oncology
Walgreens
Walmart
World Courier Group
Wuhan Chopper Biology
Zuellig Pharma China
List of Organizations Mentioned in the Report
ACM (Authority for Consumers & Markets)
Asociación Cooperativas Farmacéuticas (Acofarma)
Bundesverband des PharmazeutischenGrosshandel (PHAGRO)
China National Pharmaceutical Group
European Association of Euro-Pharmaceutical Companies (EAEPC)
European Court of Justice
European Pharmacy Network (EPN)
Food and Drug Administration (US FDA)
Institute for Pharmaeconomic Research (IPF)
Japanese Pharmaceutical Wholesalers Association
Medicaid
Medicare
National Development and Reform Commission (NDRC)
National Health Insurance (NHI)
National Health Service (NHS)
National Pharmaceutical Pricing Authority (NPPA)
The Healthcare Distribution Management Association (HDMA)
Download sample pages
Complete the form below to download your free sample pages for Pharma Wholesale and Distribution Market Forecasts 2017-2027Download sample pages
Complete the form below to download your free sample pages for Pharma Wholesale and Distribution Market Forecasts 2017-2027Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033
The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033
31 May 2023
Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
26 May 2023
Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033
The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033
24 May 2023
Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033
The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033
23 May 2023
